safe rides

Houston software company creates COVID-19 transportation app

The new tool can be used to coordinate responsible rides for passengers infected with COVID-19. Photo via Getty Images

A Houston software company has pivoted its technology to create an app that can safely transport COVID-19 patients to their quarantine location.

Mobisoft announced the launch of NEMT Pulse, a non-emergency medical transportation app to be used by schools, community health centers, hospitals, and more to easily facilitate isolated rides.

"We pivoted our NEMT software that could be implemented to safely meet the needs of those affected by COVID-19," says Shail Sinhasane, CEO of Mobisoft, in a news release. "This app provides a solution to ensure individuals who have tested positive can get to their quarantine location with one less thing to worry about."

The company has already entered into a partnership with the University of Illinois Urbana-Champaign to implement the NEMT Pulse program so that the administration can schedule transportation for students moving to and from isolation and quarantine spaces in residence halls. The process includes regular tests for drivers, specifically designed vehicles, and HIPAA compliance.

The app provides an interface for the infected student, the driver, and the admin. According to the release, the software also has the ability to use a contactless, face detection feature and also includes SOS button and more. The process includes regular tests for drivers, specifically designed vehicles, and HIPAA compliance. In addition to the Illinois college, a community health center in California is also using the NEMT Pulse platform.

The platform has interfaces for the riders, the drivers, and the admin. Image courtesy of Mobisoft

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News